Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
8-KCurrent report7/2/20217/2/2021
8-KCurrent report6/30/20216/28/2021
8-KCurrent report6/29/20216/29/2021
8-KCurrent report6/23/20216/22/2021
8-KCurrent report6/17/20216/17/2021
8-KCurrent report6/9/20216/9/2021
8-KCurrent report5/13/20215/13/2021
10-QQuarterly report [Sections 13 or 15(d)]5/13/20213/31/2021
8-KCurrent report5/6/20215/6/2021
8-KCurrent report5/4/20215/4/2021
8-KCurrent report4/28/20214/28/2021
8-KCurrent report4/28/20214/28/2021
8-KCurrent report4/27/20214/27/2021
424B3Prospectus [Rule 424(b)(3)]3/16/2021
EFFECTNotice of Effectiveness3/15/2021
CORRESPCorrespondence3/11/2021
UPLOADSEC-generated letter3/10/2021
S-8Securities to be offered to employees in employee benefit plans3/5/2021
S-1General form for registration of securities under the Securities Act of 19333/5/2021
8-KCurrent report3/4/20213/4/2021
8-KCurrent report3/3/20213/2/2021
8-KCurrent report2/16/20212/16/2021
8-KCurrent report2/12/20212/12/2021
10-QQuarterly report [Sections 13 or 15(d)]2/11/202112/31/2020
SC 13GStatement of acquisition of beneficial ownership by individuals2/9/2021
8-KCurrent report2/5/20212/5/2021
8-KCurrent report1/20/20211/20/2021
SC 13G/AStatement of acquisition of beneficial ownership by individuals - amendment1/20/2021
8-KCurrent report1/19/20211/19/2021
8-KCurrent report1/11/20211/11/2021
  • « Previous
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*